CD20+ tumour infiltrating lymphocytes (TILs), i.e. mature B cells who have undergone Ig-class switching [14], are reportedly strongly linked to an improved patient outcome in high-grade serous ovarian cancer when combined with CD8+ T cells [15]. Here, CD8A is linked to neoplasm.